Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review

Tuberculosis following programmed cell death receptor-1 (PD-1) inhibitor in a patient with non-small cell lung cancer. Case report and literature review

<p>Immune checkpoint inhibitors (ICIs)—anti-programmed death-1 (PD-1) and their ligands (PD-L1 and PD-L2) have become widely used in the treatment of several malignancies. Many immune-related adverse events (irAEs) have been linked to these agents. Nonetheless, tuberculosis (TB) reactivation d...

Full description

Saved in:
Bibliographic Details
Main Author: Aasir M. Suliman (14150217) (author)
Other Authors: Shaza A. Bek (14150220) (author), Mohamed S. Elkhatim (14150223) (author), Ahmed A. Husain (11819156) (author), Ahmad Y. Mismar (14150226) (author), M. Z. Sharaf Eldean (14150229) (author), Zsolt Lengyel (3427871) (author), Shereen Elazzazy (9545774) (author), Kakil I. Rasul (14150232) (author), Nabil E. Omar (9545756) (author)
Published: 2022
Subjects:
Oncology and carcinogenesis
Cancer Research
Oncology
Immunology
Immunology and Allergy
Tags: Add Tag
No Tags, Be the first to tag this record!
Be the first to leave a comment!
You must be logged in first

Similar Items